Reason for PBAC rejection of cancer medicines important for patients and doctors

More clarity around the reasons cancer medicines are rejected by the Pharmaceutical Benefits Advisory Committee (PBAC) would better inform discussions between clinicians and their patients, a medical oncologist says. Dr Deme Karikios, who practices at the Nepean Hospital and is a PhD candidate with the University of Sydney’s NHMRC Clinical Trials Centre, said inadequate cost-effectiveness ...